KPV Peptide: The α-MSH Tripeptide Research Guide
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), investigated primarily for its anti-inflammatory signaling properties in preclinical models. Unlike full-length α-MSH or synthetic melanotan analogs, the isolated KPV sequence dissociates immunomodulatory action from pigmentation because it lacks the binding motif required to activate melanocortin receptors MC1R and MC4R. Current laboratory research, including the 27 publications indexed on PubMed, focuses on its ability to traverse cell membranes via PepT1 transporters and inhibit NF-κB nuclear translocation in mucosal and systemic inflammation assays.
Biochemical Structure of the Lys-Pro-Val Tripeptide Sequence
KPV is a naturally occurring, three-amino-acid peptide composed of lysine, proline, and valine, representing the specific C-terminal sequence (amino acids 11-13) of native alpha-melanocyte-stimulating hormone (α-MSH). In preclinical models, this truncated molecular structure isolates the anti-inflammatory signaling domain of the parent hormone from its melanotropic segments. Researchers utilize synthesized KPV to investigate cellular transport and receptor interaction without the steric hindrance of the full 13-amino-acid α-MSH chain.
Primary Molecular Specifications
The transition from a tridecapeptide (13 residues) to a tripeptide drastically alters the compound’s mass and solubility profile in laboratory buffers. The fundamental chemical properties of the synthesized KPV reference material are outlined below.
| Property | Specification |
|---|---|
| Sequence | Lys-Pro-Val (K-P-V) |
| Formula | C16H30N4O4 |
| Molecular Weight | 342.4 g/mol |
Constituent Amino Acid Biochemistry
The distinct behavior of KPV in in-vitro assays is driven by the specific side-chain chemistry of its three constituent amino acids. The combination of a positively charged N-terminus, a rigid central ring, and a hydrophobic C-terminus creates a unique spatial conformation. This precise geometry is currently investigated for its capacity to interact with specific transporter proteins, such as PepT1, on the surface of intestinal epithelial cells.
| Amino Acid Residue | Sequence Position | Side-Chain Chemistry | Structural Contribution |
|---|---|---|---|
| Lysine (Lys / K) | N-Terminal (Position 1) | Basic, positively charged primary amine | Confers high aqueous solubility and facilitates electrostatic interactions with anionic membrane targets. |
| Proline (Pro / P) | Central (Position 2) | Cyclic, secondary aliphatic amine | Imparts structural rigidity to the peptide backbone, locking the terminal residues into a specific spatial orientation. |
| Valine (Val / V) | C-Terminal (Position 3) | Hydrophobic, branched aliphatic | Provides a non-polar domain theorized to assist in lipid bilayer interaction during transmembrane transport assays. |
Parent Sequence Truncation: α-MSH vs. KPV
Native α-MSH is cleaved from the precursor protein pro-opiomelanocortin (POMC) and possesses the amino acid sequence SYSMEHFRWGKPV. The central His-Phe-Arg-Trp (HFRW) core of α-MSH is the established pharmacophore for melanocortin receptor-1 (MC1R) binding, which induces melanogenesis. By cleaving the sequence down to the terminal KPV fragment, researchers obtain a low-molecular-weight compound that eliminates the HFRW core, thus shifting the research focus entirely away from pigmentation pathways.
| Comparative Metric | Native α-MSH | KPV Tripeptide |
|---|---|---|
| Total Amino Acids | 13 (Tridecapeptide) | 3 (Tripeptide) |
| Approximate Molecular Weight | 1664.9 g/mol | 342.4 g/mol |
| Presence of HFRW Core | Yes (Residues 6-9) | No |
| Primary Research Application | Melanocortin receptor agonism, pigmentation | Intracellular signaling, immunomodulation |
Understanding the structural biochemistry of KPV is foundational for investigating its intracellular mechanisms. Its minimal sequence focuses experimental cellular models solely on the signaling pathways associated with the Lys-Pro-Val terminus. For broader literature on peptide truncation methodologies and their structural implications, researchers can review indexing aggregators such as PubMed.
How KPV Dissociates Anti-Inflammatory Signaling from Pigmentation
The Lys-Pro-Val (KPV) tripeptide isolates the immunomodulatory properties of alpha-melanocyte-stimulating hormone (α-MSH) without inducing melanin production because it structurally lacks the central His-Phe-Arg-Trp (HFRW) pharmacophore. By omitting this core binding motif, KPV fails to trigger the classical cyclic AMP (cAMP) pathway at the melanocortin-1 receptor (MC1R). Consequently, laboratory models demonstrate that the sequence exerts anti-inflammatory signaling without initiating downstream melanogenesis.
Structural Omission of the Melanotropic Core
Full-length α-MSH is a 13-amino acid sequence that exhibits pleiotropic effects, primarily governed by its central HFRW motif spanning residues 6 through 9. This specific tetrapeptide sequence is the critical structural requirement for docking at melanocortin receptors and stimulating tyrosinase activity, the rate-limiting enzyme in melanin synthesis. The tripeptide consists solely of the C-terminal residues 11-13. The complete absence of the HFRW motif in KPV peptide synthesized for laboratory research explains its structural inability to act as a traditional melanotropic agonist.
| Peptide Sequence | Residue Position (relative to α-MSH) | Primary Structural Motif |
|---|---|---|
| α-MSH (Endogenous) | 1-13 | SYSMEHFRWGKPV |
| HFRW Fragment | 6-9 | His-Phe-Arg-Trp (Core Pharmacophore) |
| KPV | 11-13 | Lys-Pro-Val (C-Terminal Fragment) |
Differential Receptor Binding in In-Vitro Models
In classical melanocortin signaling, the HFRW sequence binds MC1R on melanocytes, initiating a G-protein coupled cascade that elevates intracellular cAMP. Preclinical receptor-binding assays indicate that while full-length α-MSH strongly upregulates cAMP, KPV does not alter baseline cAMP levels in melanocyte cultures. This biochemical divergence confirms that KPV bypasses the melanogenic activation pathway entirely, a feature frequently cross-referenced in literature indexed on databases like PubMed.
| Assay Metric | α-MSH Effect (In Vitro) | KPV Effect (In Vitro) |
|---|---|---|
| MC1R Binding Affinity | High (mediated by HFRW motif) | Negligible |
| Intracellular cAMP Levels | Significant Dose-Dependent Increase | No Deviation from Baseline |
| Tyrosinase Transcription | Upregulated | Unchanged |
Isolating the Immunomodulatory Sequence
Because KPV dissociates from pigmentation pathways, researchers utilize the tripeptide to investigate localized inflammatory modulation without confounding melanogenic variables. In-vitro intestinal epithelial and keratinocyte models demonstrate that KPV achieves this by migrating intracellularly—often utilizing PepT1 transporters—to inhibit NF-κB nuclear translocation. This distinct mechanism highlights how the C-terminal sequence operates independently of the extracellular melanocortin receptor activation demanded by the HFRW core.
| Cellular Response Profile | Phenotypic Observation (In Vitro) | Primary Signaling Mechanism |
|---|---|---|
| Melanogenesis (Pigmentation) | Absent | Lack of MC1R-cAMP activation |
| NF-κB Inhibition | Present | Intracellular transporter uptake (e.g., PepT1) |
| Pro-inflammatory Cytokine Suppression | Present | Transcriptional downregulation |
Mechanisms of Intracellular Entry: The Role of PepT1 Transporters
KPV (Lys-Pro-Val) differentiates itself from larger alpha-melanocyte-stimulating hormone (α-MSH) analogs by utilizing the human peptide transporter 1 (hPepT1) for intracellular entry, rather than relying exclusively on extracellular melanocortin receptor binding. Preclinical intestinal epithelial cell models demonstrate that hPepT1 actively internalizes the tripeptide, allowing it to interact directly with cytosolic signaling complexes. This proton-coupled transport mechanism bypasses traditional surface-level receptor cascades, providing a specific pathway for localized intracellular investigation.
How the SLC15A1 Gene Product Recognizes Lys-Pro-Val
The hPepT1 transporter, encoded by the SLC15A1 gene, functions as a high-capacity, low-affinity proton-coupled oligopeptide transporter primarily localized to the apical membrane of intestinal enterocytes. In vitro assays indicate that hPepT1 specifically recognizes dipeptides and tripeptides, excluding free amino acids or peptides exceeding three residues in length. This strict structural limitation aligns perfectly with the three-amino-acid sequence of KPV. Literature indexed in PubMed suggests that the proton electrochemical gradient across the apical membrane drives the active translocation of KPV into the cytosol against its concentration gradient.
| Transporter Property | Mechanism / Specificity |
|---|---|
| Gene Origin | SLC15A1 |
| Driving Force | Proton (H+) electrochemical gradient |
| Substrate Specificity | Dipeptides and tripeptides exclusively |
| Target Tripeptide | Lys-Pro-Val (KPV) |
Bypassing Extracellular Melanocortin Receptors
Classical α-MSH research focuses on G-protein-coupled receptor (GPCR) activation, specifically via melanocortin receptors (MC1R through MC5R) positioned on the extracellular membrane. Preclinical models investigating KPV demonstrate a divergent pathway. By entering the cell via hPepT1, KPV bypasses the requirement for surface receptor binding. Cellular models utilizing Caco-2 monolayers—a standard for simulating the human intestinal epithelial barrier—reveal that knocking down hPepT1 expression significantly attenuates KPV’s intracellular signaling effects, confirming the transporter’s obligate role in the peptide’s cellular entry.
| Mechanism Feature | Classical α-MSH Signaling | KPV Transporter Entry |
|---|---|---|
| Primary Cellular Target | Extracellular Melanocortin Receptors (MC1R, MC3R-5R) | Apical Membrane Transporter (hPepT1) |
| Cellular Translocation | Remains extracellular (ligand-receptor complex) | Complete internalization into cytosol |
| Signaling Cascade Origin | Membrane-bound adenylyl cyclase activation | Direct cytosolic interaction |
In Vitro Methodologies for Measuring Transporter Kinetics
To isolate the kinetics of hPepT1-mediated KPV transport, researchers frequently employ competitive inhibition assays. In these laboratory models, the introduction of established hPepT1 substrates, such as glycylsarcosine (Gly-Sar), competitively inhibits the cellular uptake of KPV. Tracking radiolabeled or fluorescently tagged KPV in the presence or absence of a proton gradient further validates the dependency on hPepT1. These investigative frameworks allow researchers to quantify the maximum transport velocity (Vmax) and the Michaelis constant (Km) for the Lys-Pro-Val sequence in controlled environments.
| Assay Type | Experimental Purpose | Observed Preclinical Dynamics |
|---|---|---|
| Competitive Inhibition | Verify hPepT1 substrate specificity | Gly-Sar introduction reduces KPV intracellular concentration |
| Proton Gradient Manipulation | Confirm driving force dependency | Alkaline extracellular pH eliminates active KPV transport |
| Gene Knockdown (siRNA) | Isolate SLC15A1 function | Silencing hPepT1 halts KPV-mediated cytosolic signaling |
Inhibition of NF-κB Nuclear Translocation in Preclinical Models
KPV (Lys-Pro-Val) exerts its primary anti-inflammatory influence by stabilizing the inhibitory protein IκBα within the cellular cytoplasm. This stabilization prevents the p65 subunit of nuclear factor kappa B (NF-κB) from translocating to the nucleus, thereby halting the transcription of pro-inflammatory cytokines. In vitro and murine models consistently demonstrate that this intracellular cascade rapidly downregulates the expression of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8).
The IκBα Stabilization Cascade
Following intracellular transport via PepT1 transporters, KPV interacts with the NF-κB signaling complex. Under standard inflammatory conditions, IκB kinase (IKK) phosphorylates IκBα, marking it for proteasomal degradation. This degradation exposes the nuclear localization signals on NF-κB dimers. Preclinical literature indicates KPV interrupts this step, maintaining IκBα structural integrity even in the presence of robust inflammatory stimuli like lipopolysaccharide (LPS).
| Target Cytokine | Modulation Effect | Model Observed |
|---|---|---|
| TNF-α | Downregulated | Intestinal Epithelial Cells |
| IL-6 | Downregulated | Murine Colitis Model |
| IL-8 | Downregulated | In-vitro Keratinocytes |
Cytokine Downregulation Profiles in Literature
By sequestering the transcription factor in the cytosol, KPV directly suppresses the mRNA expression of downstream inflammatory mediators. Researchers investigating mucosal and cutaneous inflammation utilize these models to quantify the peptide’s cellular efficacy compared to full-length α-MSH. The resulting state of the signaling pathway demonstrates a clear interruption of standard pro-inflammatory feedback loops.
| Pathway Component | Normal Inflammatory State | Observed State with KPV |
|---|---|---|
| IκBα | Phosphorylated & Degraded | Stabilized & Intact |
| NF-κB (p65) | Translocated to Nucleus | Sequestered in Cytosol |
| Pro-inflammatory mRNA | Actively Transcribed | Transcription Suppressed |
Quantifying Nuclear Translocation in Assays
Laboratory verification of this mechanism relies on precise analytical techniques to separate cellular compartments. Electrophoretic mobility shift assays (EMSA) and Western blotting of fractionated cell lysates allow researchers to confirm the physical absence of the p65 subunit in the nuclear fraction. Investigators routinely reference the PubMed literature on KPV peptide NF-kB interactions to replicate these assay protocols in novel cell lines.
| Analytical Technique | Laboratory Purpose | KPV Research Application |
|---|---|---|
| Western Blot (Fractionated) | Protein localization | Quantifying cytosolic vs. nuclear p65 |
| EMSA | DNA-binding activity | Measuring NF-κB binding to promoter regions |
| RT-PCR | Gene expression | Quantifying downstream TNF-α/IL-6 mRNA |
Receptor-Mediated vs. Intracellular Action: The Ongoing Mechanistic Debate
The mechanistic debate surrounding the Lys-Pro-Val (KPV) tripeptide centers on whether it exerts its immunomodulatory effects strictly via PepT1-mediated intracellular internalization or if it retains weak affinity for surface-level melanocortin receptors. Current in vitro literature predominantly supports a cytosolic mechanism where KPV inhibits NF-κB translocation directly after cellular entry. However, isolated cell-line assays suggest potential uncharacterized membrane interactions, complicating the definitive classification of its signal transduction pathway.
Does KPV Retain Melanocortin Receptor Affinity Without the His-Phe-Arg-Trp Motif?
Endogenous α-MSH binds to the melanocortin 1 receptor (MC1R) via its central core sequence, His-Phe-Arg-Trp (amino acids 6-9). Because KPV represents only the C-terminal residues (amino acids 11-13), it lacks this classic pharmacophore. Receptor binding assays investigated in preclinical models demonstrate that KPV exhibits negligible affinity for MC1R when compared to the full-length α-MSH peptide. Researchers searching the literature (see PubMed data on KPV melanocortin receptor interactions) note that despite this lack of structural binding elements, KPV replicates specific anti-inflammatory downstream effects of α-MSH, prompting rigorous inquiries into alternative signaling routes.
| Peptide Sequence | Primary Pharmacophore | MC1R Binding Affinity (In Vitro) | Primary Subcellular Target |
|---|---|---|---|
| α-MSH (Full Length) | His-Phe-Arg-Trp (6-9) | High (Nanomolar range) | Extracellular (GPCR surface binding) |
| KPV (C-Terminal) | Lys-Pro-Val (11-13) | Negligible to Undetectable | Intracellular (Cytosolic NF-κB complex) |
PepT1 Internalization vs. Surface Binding in Cellular Models
Epithelial cell models heavily express the oligopeptide transporter PepT1 (SLC15A1). When researchers utilize PepT1 inhibitors or genetic knockdown models, KPV frequently loses its ability to attenuate pro-inflammatory cytokine expression. This data strongly supports the hypothesis that KPV acts exclusively as an intracellular agent. Conversely, certain keratinocyte and fibroblast cell lines exhibiting low PepT1 expression still demonstrate phenotypic responses to KPV exposure. This discrepancy suggests the possibility of alternative entry mechanisms or weak interactions with uncharacterized surface receptors distinct from the classic melanocortin family.
| Cellular Model Type | PepT1 Expression Level | Observed KPV Uptake Mechanism | Response to PepT1 Knockdown |
|---|---|---|---|
| Intestinal Epithelial (Caco-2) | High | Active transport via SLC15A1 | Loss of NF-κB inhibition |
| Keratinocytes (HaCaT) | Low | Potential passive diffusion or unknown receptor | Partial retention of anti-inflammatory signaling |
| Macrophages (RAW 264.7) | Variable | Pinocytosis / Unknown transporters | Variable signal attenuation |
Uncharacterized Surface Interactions in Non-Epithelial Assays
To delineate between membrane retention and cytosolic accumulation, laboratory protocols frequently employ radiolabeled KPV or fluorescent tagging. Fractionation of cell lysates following KPV incubation reveals that the vast majority of the peptide localizes within the cytoplasm, specifically interacting with IκB kinase (IKK) complexes. Yet, transient membrane localization spikes observed in early temporal assays leave the receptor-mediated hypothesis partially viable. Ongoing investigations (PubMed research on KPV peptide mechanisms) continue to evaluate whether these membrane spikes represent brief receptor agonism prior to internalization or simply the kinetic bottleneck of transporter-mediated cellular entry.
| Assay Methodology | Target Measurement | Primary Findings for KPV |
|---|---|---|
| Radioligand Binding Assay | Membrane receptor affinity | No sustained displacement of competitive MC1R ligands. |
| Subcellular Fractionation | Peptide localization post-incubation | High concentration in cytosolic fractions; low membrane retention. |
| Kinase Activity Profiling | Direct protein-protein interaction | Direct binding and stabilization of the IKK complex in vitro. |
KPV in Mucosal Inflammation and Intestinal Epithelial Research
Preclinical literature identifies the KPV tripeptide as a potent modulator of mucosal inflammation, particularly within intestinal epithelial tissues. In laboratory assays evaluating experimental colitis and mucosal injury, KPV demonstrates the capacity to suppress pro-inflammatory cytokine expression and preserve epithelial tight junctions without triggering melanogenic pathways. These observations position the peptide as a primary candidate for investigating targeted interventions in gastrointestinal inflammatory cascades.
Mechanisms of Intestinal Barrier Modulation
The intestinal epithelium expresses the oligopeptide transporter PepT1, which facilitates the intracellular uptake of KPV into intestinal epithelial cells (IECs). Once internalized, in vitro research indicates that KPV inhibits the nuclear translocation of NF-κB, a central transcription factor in the inflammatory response. By preventing NF-κB from binding to DNA, the peptide downregulates the transcription of various pro-inflammatory mediators that typically drive mucosal damage.
| Cytokine Target | Preclinical Observation in IECs | Associated Signaling Pathway |
|---|---|---|
| TNF-α | Suppressed expression following peptide exposure | NF-κB inhibition |
| IL-8 | Reduced secretion in stimulated Caco-2 monolayers | MAPK / NF-κB |
| IL-6 | Decreased transcript levels in inflamed tissues | STAT3 / NF-κB |
Preclinical Models of Experimental Colitis
Animal models of Inflammatory Bowel Disease (IBD), such as Dextran Sulfate Sodium (DSS) and Trinitrobenzene Sulfonic acid (TNBS) induced colitis, serve as the standard for evaluating mucosal integrity. Investigators utilizing research-grade KPV for mucosal inflammation experiments report that the tripeptide mitigates macroscopic and microscopic tissue damage in these models. Morphological evaluations frequently note reduced immune cell infiltration, preserved crypt architecture, and minimized ulceration in the colonic mucosa of peptide-exposed subjects.
| Preclinical Model | Mechanism of Epithelial Injury | Primary Evaluation Metrics |
|---|---|---|
| DSS-Induced Colitis | Chemical disruption of the mucosal barrier | Histological scoring, colon length, myeloperoxidase (MPO) activity |
| TNBS-Induced Colitis | Hapten-mediated cell-mediated immune response | T-cell infiltration, cytokine profiling, mucosal necrosis |
| Caco-2 Cell Monolayers | In vitro pro-inflammatory cytokine stimulation | Trans-Epithelial Electrical Resistance (TEER), ZO-1 expression |
Epithelial Restitution and Tight Junction Integrity
Beyond systemic inflammatory suppression, laboratory data suggest KPV actively supports epithelial restitution. In trans-well cellular assays, the peptide accelerates the closure of mechanically induced epithelial wounds. Researchers measuring barrier function using Trans-Epithelial Electrical Resistance (TEER) observe that KPV administration in vitro prevents the catastrophic drop in TEER typically induced by inflammatory agents. This preservation is largely attributed to the stabilization of tight junction proteins, specifically Zonula Occludens-1 (ZO-1) and Claudin-1, which maintain paracellular permeability.
| Integrity Biomarker | Function in Mucosal Barrier | Observed Impact of KPV in Assays |
|---|---|---|
| TEER (Trans-Epithelial Electrical Resistance) | Quantifies paracellular permeability and barrier strength | Attenuates inflammation-induced TEER degradation |
| ZO-1 (Zonula Occludens-1) | Anchors tight junction strands to the actin cytoskeleton | Prevents tight junction disruption and protein depletion |
| MPO (Myeloperoxidase) | Enzyme indicating neutrophil infiltration and oxidative stress | Reduces mucosal MPO activity in murine colitis models |
For ongoing tracking of these experimental models and in vivo findings, investigators can query the current literature via the National Library of Medicine: https://pubmed.ncbi.nlm.nih.gov/?term=KPV+peptide+colitis and https://pubmed.ncbi.nlm.nih.gov/?term=KPV+intestinal+inflammation.
Differentiating KPV from Melanotan I and Melanotan II
The KPV tripeptide diverges fundamentally from Melanotan I and Melanotan II in both molecular architecture and receptor pharmacology. While all three compounds originate from research into alpha-melanocyte-stimulating hormone (α-MSH), Melanotan peptides are engineered specifically to agonize melanocortin receptors and induce melanogenesis. Conversely, KPV isolates the anti-inflammatory C-terminal sequence of α-MSH, bypassing melanocortin receptor activation entirely to exert effects without triggering pigmentation.
Melanotan I (MT-I) and Melanotan II (MT-II) incorporate D-amino acids and substituted residues to resist enzymatic degradation while maximizing binding affinity at the melanocortin 1 receptor (MC1R). MT-I is a linear, full-length analog featuring a Norleucine substitution and a D-Phenylalanine enantiomer to increase structural stability. MT-II compresses the active sequence into a cyclic heptapeptide, utilizing a lactam bridge to lock the molecule into a conformation that aggressively binds MC1R, alongside MC3R, MC4R, and MC5R. KPV, consisting exclusively of Lysine, Proline, and Valine, lacks the core His-Phe-Arg-Trp pharmacophore required for melanocortin receptor activation.
| Peptide | Primary Target | Pigmentation Induction | Structure |
|---|---|---|---|
| KPV | Unknown/Intracellular (PepT1) | None observed | Linear Tripeptide |
| Melanotan I | MC1R | High | Linear Analog |
| Melanotan II | MC1R, MC3R-5R | Very High | Cyclic Heptapeptide |
Molecular Sequence and Structural Modifications
The structural variations dictate the distinct preclinical applications of these peptides. The compact, cyclic nature of Melanotan II permits broad receptor engagement, heavily researched for systemic melanogenic and metabolic responses. KPV remains strictly linear and truncated, limiting its extracellular binding while facilitating transport across cellular membranes via PepT1 transporters.
| Peptide | Sequence Profile | Structural Classification |
|---|---|---|
| KPV | Lys-Pro-Val | Truncated Linear Tripeptide |
| Melanotan I | Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 | Substituted Linear Tridecapeptide |
| Melanotan II | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 | Cyclic Heptapeptide |
Receptor Binding and Functional Outcomes
In vitro investigations demonstrate that agonizing MC1R stimulates the adenylyl cyclase pathway, increasing cyclic AMP (cAMP) and initiating melanin synthesis. Melanotan I and Melanotan II both trigger this cascade robustly in laboratory models. Because KPV lacks the melanocortin-binding sequence, researchers observe no melanogenic activity during isolated KPV exposure. Instead, KPV modulates inflammatory cascades intracellularly. For broader literature on these divergent mechanisms, researchers consult PubMed investigations regarding KPV and melanocortin receptors, as well as studies on Melanotan MC1R pigmentation.
| Peptide | MC1R Affinity (Melanogenesis) | Off-Target Melanocortin Activity (MC3R-MC5R) |
|---|---|---|
| KPV | Negligible | None observed |
| Melanotan I | High | Low/Moderate |
| Melanotan II | Very High | High |
Antimicrobial and Fungicidal Properties Observed In Vitro
KPV demonstrates concentration-dependent antimicrobial and fungicidal activity in laboratory settings, functioning primarily through microbial membrane disruption and the modulation of intracellular signaling within target pathogens. Preclinical assays indicate that the Lys-Pro-Val sequence exhibits broad-spectrum inhibitory potential against specific Gram-negative bacteria, Gram-positive bacteria, and fungal strains. These in vitro properties position the tripeptide as a dual-action research compound, simultaneously attenuating host-cell inflammatory cascades while exerting direct cytolytic effects on microbial targets.
Mechanisms of Microbial Membrane Disruption
The antimicrobial efficacy of the KPV peptide is structurally dependent on the N-terminal lysine residue. In physiological pH environments, the epsilon-amino group of lysine carries a positive charge, conferring cationic properties to the tripeptide. This cationic localized charge facilitates electrostatic binding to the anionic phospholipid bilayers characteristic of bacterial and fungal cell membranes. Following surface accumulation, research indicates that KPV induces transient membrane depolarization and localized pore formation, compromising cellular integrity.
| Proposed Mechanism | Biochemical Target | Laboratory Observation |
|---|---|---|
| Electrostatic Attraction | Anionic Phospholipid Headgroups | Peptide accumulation on the exterior microbial cell envelope. |
| Membrane Depolarization | Lipid Bilayer Gradient | Loss of transmembrane potential leading to ion leakage. |
| Pore Formation | Cell Wall Integrity | Direct cytolysis and subsequent microbial apoptosis in cell cultures. |
Concentration-Dependent Pathogen Inhibition Profiles
In vitro susceptibility assays demonstrate that KPV effectively inhibits colony-forming units (CFUs) in a concentration-dependent manner. Literature accessible via PubMed highlights distinct inhibitory thresholds for pathogens such as Staphylococcus aureus and Escherichia coli. Unlike conventional antibiotics that target specific enzymatic pathways, KPV’s physical disruption of the lipid envelope reduces the likelihood of rapid microbial adaptation in isolated cell cultures.
| Microorganism Classification | Specific Pathogen Evaluated | Observed In Vitro Effect |
|---|---|---|
| Gram-Positive Bacteria | Staphylococcus aureus | Concentration-dependent reduction in viable CFUs and arrested replication. |
| Gram-Negative Bacteria | Escherichia coli | Destabilization of the outer membrane lipopolysaccharide (LPS) layer. |
| Dimorphic Fungi | Candida albicans | Suppression of germ tube formation and hyphal elongation. |
Fungicidal Activity and Biofilm Interference
Beyond bactericidal observations, KPV exhibits potent fungicidal properties, particularly in models evaluating Candida albicans. Laboratory investigations show that the tripeptide interferes with cyclic AMP (cAMP) production within the yeast, a necessary signaling molecule for the dimorphic transition from benign yeast forms to virulent hyphal structures. By blocking this morphological shift, KPV prevents the subsequent establishment of robust extracellular biofilms. Researchers tracking these assays often utilize PubMed literature to compare the peptide’s efficacy against standard antifungal agents in standardized microbroth dilution tests.
| Fungal Target Structure | KPV Interaction Mechanism | Phenotypic Outcome in Assays |
|---|---|---|
| Adenylyl Cyclase | Inhibition of cAMP synthesis | Prevention of yeast-to-hyphae morphological transition. |
| Extracellular Matrix (ECM) | Interference with EPS secretion | Arrested biofilm maturation and reduced adherence to abiotic surfaces. |
| Ergosterol Bilayer | Cationic membrane insertion | Fungal cell lysis independent of traditional sterol-binding pathways. |
Stability, Degradation, and Formulation Chemistry in the Laboratory
The Lys-Pro-Val (KPV) tripeptide exhibits distinct physicochemical vulnerabilities inherent to short, linear amino acid sequences, primarily a high susceptibility to rapid proteolytic cleavage by ubiquitous exopeptidases. To mitigate this degradation in laboratory environments, researchers employ structural modifications such as N-terminal acetylation and C-terminal amidation, alongside precise pH and temperature controls during aqueous formulation. These stabilization strategies are critical for maintaining peptide integrity during extended in vitro cellular assays and pharmacokinetic modeling.
Mechanisms of Proteolytic Cleavage in Linear Tripeptides
Short linear peptides lack the secondary and tertiary structures that shield larger proteins from enzymatic degradation. In the KPV sequence, the exposed N-terminal lysine and C-terminal valine present immediate targets for exopeptidases in biological matrices. Aminopeptidases rapidly hydrolyze the peptide bond adjacent to the N-terminal lysine. Conversely, carboxypeptidases target the carboxyl group of the C-terminal valine. While the central proline residue introduces structural rigidity and provides specific steric hindrance against endopeptidase activity, the overall unmodified sequence remains highly labile.
| Enzyme Class | Target Residue in KPV | Mechanism of Degradation |
|---|---|---|
| Aminopeptidases | N-terminal Lysine (Lys) | Hydrolytic cleavage of the primary amine peptide bond. |
| Carboxypeptidases | C-terminal Valine (Val) | Excision of the terminal amino acid at the carboxyl end. |
| Endopeptidases | Internal Peptide Bonds | Resisted heavily by the central Proline residue’s ring structure. |
Structural Modifications for Enhanced In Vitro Stability
To extend the half-life of KPV during preclinical investigations, laboratories frequently utilize synthesized analogs featuring terminal modifications. Acetylation of the N-terminus (forming Ac-KPV) masks the primary amine group, drastically reducing aminopeptidase affinity. Concurrently, amidation of the C-terminus (forming KPV-NH2) removes the negative charge of the carboxyl group, blocking carboxypeptidase recognition and enhancing the overall neutrality of the molecule. These chemical alterations ensure the peptide remains intact long enough to interact with cellular targets like PepT1 transporters. Literature detailing these synthetic modifications is accessible via PubMed searches on KPV peptide stability.
| Chemical Modification | Structural Alteration | Protective Effect in Preclinical Models |
|---|---|---|
| N-terminal Acetylation | Addition of an acetyl group to Lysine. | Neutralizes positive charge; blocks aminopeptidase docking. |
| C-terminal Amidation | Replacement of hydroxyl group with an amide on Valine. | Removes negative charge; prevents carboxypeptidase cleavage. |
| D-Amino Acid Substitution | Chiral inversion (e.g., D-Lys-D-Pro-D-Val). | Renders the sequence unrecognizable to natural proteolytic enzymes. |
Aqueous Formulation and Laboratory Storage Parameters
The physical environment heavily dictates KPV’s degradation kinetics. Unbuffered aqueous formulations are susceptible to hydrolysis and oxidation. Researchers typically maintain a slightly acidic to neutral pH (5.5 to 7.0) in solution to minimize the spontaneous hydrolysis of peptide bonds. For long-term archiving, laboratories maintain KPV in a lyophilized (freeze-dried) state at sub-zero temperatures. Reconstitution protocols strictly dictate the use of sterile, buffered solvents immediately prior to running assays to prevent rapid structural degradation.
| Storage State | Optimal Temperature | Degradation Risk Profile |
|---|---|---|
| Lyophilized Powder | -20°C to -80°C | Minimal; highly stable for multi-year laboratory archiving. |
| Reconstituted (Aqueous) | 2°C to 8°C | Moderate; susceptible to slow hydrolysis over 14-21 days. |
| Reconstituted (Room Temp) | 20°C to 25°C | High; rapid enzymatic and hydrolytic degradation within 24-48 hours. |
Synergistic Preclinical Research: KPV Combined with Hyaluronic Acid
Conjugating or co-administering the Lys-Pro-Val (KPV) tripeptide with hyaluronic acid (HA) modifies its physiochemical profile in preclinical models, enhancing localized tissue retention and enabling controlled release. Experimental formulations leverage HA’s viscoelastic properties to increase KPV’s stability and tissue permeation in in vitro dermatological assays. This synergistic approach actively addresses the rapid proteolytic degradation typically observed when investigating isolated short-chain peptides in biological media.
Formulation Dynamics: Covalent Conjugation vs. Physical Co-Administration
Researchers utilize two primary methodologies to combine these compounds: covalent conjugation and physical hydrogel entrapment. Covalent linkage often employs EDC/NHS coupling chemistry to attach KPV’s primary amines to HA’s carboxyl groups, creating a conjugated macromolecule with sustained release kinetics. Conversely, physical co-administration suspends the peptide within an HA matrix, relying on passive diffusion rates through the polymer network. When sourcing synthetic KPV peptide for complex hydrogel arrays, investigators must account for these differential release mechanisms to ensure consistent exposure over the targeted cellular assay duration.
| Formulation Strategy | Chemical Mechanism | In Vitro Release Kinetics | Primary Laboratory Application |
|---|---|---|---|
| Covalent Conjugation | Amide bond formation (EDC/NHS) | Slow, sustained, enzyme-dependent | Long-term cellular exposure assays |
| Physical Entrapment | Suspension in polymer matrix | Initial burst, followed by diffusion | Acute localized ECM studies |
| Liposomal HA-Coating | Encapsulation with HA exterior | Triggered release upon membrane fusion | Targeted intracellular delivery models |
Modulating Penetration via HA Molecular Weight
The molecular weight (MW) of the hyaluronic acid backbone strictly governs the permeation depth of the KPV payload in Franz diffusion cell studies. High molecular weight (HMW) HA restricts systemic absorption, anchoring the KPV at the application site to form a localized topical depot. Low molecular weight (LMW) HA acts as a biological penetration enhancer, facilitating KPV transport deeper into synthetic dermal equivalents.
| HA Variant | Molecular Weight Range | Matrix Characteristic | KPV Permeation Profile (In Vitro) |
|---|---|---|---|
| Oligomeric HA | <10 kDa | Highly fluid, non-viscous | Rapid trans-stratum corneum transit |
| Low MW (LMW) | 10 kDa – 250 kDa | Moderate viscosity | Deep dermal layer penetration |
| High MW (HMW) | >1,000 kDa | Rigid hydrogel scaffold | Surface retention and slow diffusion |
Observations in Cutaneous and Extracellular Matrix Assays
In laboratory models evaluating tissue remodeling, KPV-HA complexes exhibit specific measurable effects on extracellular matrix (ECM) components. Fibroblast migration assays demonstrate that HA provides a structural scaffold, while KPV simultaneously modulates the local biochemical milieu by suppressing NF-κB nuclear translocation. This structural-biochemical dual action is frequently tracked in the literature evaluating KPV and hyaluronic acid, specifically regarding how localized peptide retention alters keratinocyte proliferation rates.
| Preclinical Assay Type | Cell Line / Medium | Measured Parameter | Typical In Vitro Observation |
|---|---|---|---|
| Scratch Wound Assay | Human Dermal Fibroblasts (HDFs) | Rate of gap closure | Accelerated cellular migration |
| Franz Diffusion Cell | Porcine ear skin or synthetic membrane | Cumulative peptide permeation | MW-dependent retention profiling |
| Cytokine Quantification | LPS-stimulated Macrophages | TNF-α and IL-6 levels | Synergistic suppression vs. KPV alone |
Investigational Models for Dermatological and Cutaneous Inflammation
In-vitro models of cutaneous inflammation indicate that the Lys-Pro-Val (KPV) tripeptide downregulates pro-inflammatory cytokine expression in epidermal cells without inducing melanogenesis. Preclinical research focusing on psoriasis and contact dermatitis models demonstrates that KPV modulates inflammatory signaling primarily by inhibiting NF-κB nuclear translocation. This action suppresses the localized synthesis of chemokines and cytokines, establishing the peptide as a primary subject in dermatological research evaluating non-steroidal modulation of skin inflammation.
How Does KPV Modulate Keratinocyte Signaling in Psoriasis Models?
Keratinocytes are the primary cellular targets in psoriasis research, characterized by hyperproliferation and chronic inflammatory signaling. In isolated keratinocyte cultures exposed to inflammatory stimuli, researchers evaluate KPV for its capacity to blunt the activation of the NF-κB and MAPK pathways. Laboratory observations report that KPV limits the intracellular degradation of IκBα, preventing the translocation of the NF-κB p65 subunit to the nucleus. This mechanistic blockade correlates with a measurable reduction in the transcription of interleukin-8 (IL-8), a primary chemoattractant for neutrophils in psoriatic plaques, as well as tumor necrosis factor-alpha (TNF-α).
| Target Cytokine | Role in Cutaneous Inflammation Models | Observed KPV Modulation (In-Vitro) |
|---|---|---|
| IL-8 (CXCL8) | Neutrophil recruitment and epidermal hyperproliferation. | Downregulated transcription via NF-κB inhibition. |
| TNF-α | Primary inflammatory amplifier in psoriatic models. | Suppressed secretion in stimulated keratinocytes. |
| IL-1β | Initiator of the local acute phase response. | Decreased mRNA expression in fibroblast co-cultures. |
Which Experimental Paradigms Assess KPV in Contact Dermatitis?
In-vitro representations of allergic and irritant contact dermatitis rely on co-cultures of keratinocytes, fibroblasts, and immune cells such as mast cells. When these models are challenged with contact sensitizers (e.g., dinitrofluorobenzene or metal salts), they rapidly release inflammatory mediators. Experimental application of KPV in these assays investigates its capacity to attenuate mast cell degranulation and histamine release. Literature available on PubMed indicates that the tripeptide restricts the initial inflammatory cascade, limiting the subsequent activation of antigen-presenting cells in the localized skin model.
| Dermatological Model Type | Primary Cell Lines Utilized | Key Research Biomarkers Assessed |
|---|---|---|
| Psoriasis (Hyperproliferation) | HaCaT (human immortalized keratinocytes) | Ki-67 expression, IL-17, IL-22, IL-8 |
| Contact Dermatitis (Irritant) | Keratinocyte/Fibroblast 3D co-cultures | Histamine release, prostaglandin E2 (PGE2) |
| General Cutaneous Inflammation | Primary human epidermal keratinocytes (NHEK) | NF-κB nuclear localization, ROS generation |
What Physicochemical Properties Govern Cutaneous Diffusion Research?
For in-vitro dermatological studies, a compound must demonstrate specific structural characteristics to penetrate synthetic stratum corneum membranes or excised skin samples in Franz diffusion cells. The Lys-Pro-Val sequence possesses an exceptionally low molecular mass, facilitating diffusion studies without the immediate need for complex liposomal encapsulation, though nanocarrier formulations are actively researched to prolong localized half-life. Researchers investigating peptide permeation frequently analyze these baseline structural metrics to optimize topical research formulations.
| Physicochemical Property | Value for Lys-Pro-Val (KPV) | Relevance to In-Vitro Skin Models |
|---|---|---|
| Molecular Weight | 383.48 g/mol | Well below the 500 Dalton rule, enabling passive diffusion studies. |
| Isoelectric Point (pI) | ~9.8 | Positively charged at physiological pH, influencing membrane interaction. |
| Hydrophilicity | High (due to basic Lysine residue) | Requires specific solvent ratios (e.g., aqueous/ethanol) for permeation assays. |
Investigational data concerning these cellular mechanisms undergoes continuous expansion; researchers can track ongoing preclinical and assay evaluations via ClinicalTrials.gov.
Current Literature Metrics and PubMed Research Trends
An analysis of current scientific databases reveals exactly 27 preclinical publications investigating the Lys-Pro-Val (KPV) sequence, with zero registered human trials to date. A review of PubMed confirms research focus remains strictly on in vitro and animal models exploring NF-κB inhibition and PepT1-mediated cellular entry. According to ClinicalTrials.gov, no clinical investigations exist, reinforcing KPV’s classification exclusively as an investigational research chemical for laboratory use.
How Are the 27 Preclinical Publications Categorized by Mechanism?
The available literature investigating KPV isolates specific biochemical interactions distinct from the parent α-MSH molecule. Researchers primarily design assays to observe the tripeptide’s capacity to modulate pro-inflammatory cytokines without activating the melanocortin-1 receptor (MC1R). The 27 documented studies predominantly divide into three distinct laboratory focus areas: intracellular transport kinetics, mucosal inflammatory modeling, and pathogen-host interaction assays.
| Research Focus Area | Primary Experimental Models | Observed Biochemical Targets |
|---|---|---|
| Intracellular Transport | Caco-2 cell monolayers | PepT1 transporter affinity, cytosolic accumulation |
| Mucosal Inflammation | Murine DSS-induced colitis models | NF-κB nuclear translocation, IL-8 expression |
| Antimicrobial Activity | In vitro yeast and bacterial cultures | Biofilm disruption, cAMP pathway modulation |
Which Molecular Pathways Dominate Current KPV Database Queries?
Search query data indicates researchers investigating KPV prioritize its anti-inflammatory signaling dissociation. Unlike full-length α-MSH, which binds surface melanocortin receptors to induce pigmentation, KPV relies on PepT1 oligopeptide transporters to cross the cellular membrane. Once in the cytosol, literature reports indicate the tripeptide interacts with the IκB kinase (IKK) complex. This interaction inhibits the degradation of IκBα, thereby sequestering NF-κB in the cytoplasm and halting the transcription of pro-inflammatory mediators.
| Database | Search Parameters | Current Documented Results |
|---|---|---|
| PubMed | “alpha-MSH KPV” OR “Lys-Pro-Val” | 27 peer-reviewed preclinical papers |
| ClinicalTrials.gov | “KPV peptide” | 0 registered investigations |
Why Do Current Metrics Reflect Zero Clinical Translation?
The absence of clinical trials underscores the strict investigational nature of KPV. While the Lys-Pro-Val sequence demonstrates high stability in controlled aqueous environments and distinct molecular targeting in vitro, comprehensive pharmacokinetic profiling remains absent from the literature. Researchers utilize KPV as a highly specific probe to understand NF-κB signaling pathways and PepT1 transport mechanics rather than studying the compound for systemic human administration.
| Development Phase | Current Literature Status | Investigational Utility |
|---|---|---|
| In Vitro Assays | Extensive (Cellular models) | Receptor dissociation, pathway mapping |
| In Vivo Murine Models | Limited (Specific pathology models) | Biomarker tracking, tissue stability |
| Human Clinical Trials | None (0 registered trials) | Not applicable; strictly research chemical |
Frequently Asked Questions About KPV
What is the exact amino acid sequence of the KPV peptide?
KPV is a tripeptide consisting of the amino acids Lysine, Proline, and Valine. It corresponds to the terminal 11-13 sequence (Lys-Pro-Val) of the naturally occurring 13-amino-acid alpha-melanocyte-stimulating hormone (α-MSH).
Does KPV cause skin darkening or pigmentation?
Preclinical research indicates that KPV does not induce pigmentation. It lacks the specific His-Phe-Arg-Trp binding motif required to activate the MC1R receptor, which is the primary pathway for melanogenesis and skin darkening associated with full-length α-MSH.
How does the KPV peptide enter target cells?
In-vitro studies on intestinal epithelial cells demonstrate that KPV transports across the cell membrane primarily via the human peptide transporter 1 (PepT1). This allows the tripeptide to exert intracellular effects rather than relying solely on extracellular receptor binding.
What is the primary mechanism of action for KPV?
The dominant mechanism observed in laboratory models is the inhibition of the NF-κB inflammatory pathway. By preventing the nuclear translocation of NF-κB, KPV reduces the transcription and release of pro-inflammatory cytokines such as IL-6 and IL-8.
Is KPV the same as Melanotan 2?
No, KPV is structurally and functionally distinct from Melanotan 2. While Melanotan 2 is a synthetic, cyclic peptide designed to strongly activate melanocortin receptors for pigmentation and metabolic effects, KPV is a non-pigmenting, linear tripeptide fragment studied for anti-inflammatory signaling.
Are there human clinical trials investigating the KPV tripeptide?
Current searches of clinical databases yield zero registered clinical trials for KPV as an isolated therapeutic. It remains strictly an investigational compound utilized in in-vitro and animal models to study mucosal and systemic inflammation.
Why do researchers study KPV for inflammatory bowel disease models?
KPV is studied in IBD models because of its high affinity for PepT1 transporters expressed on intestinal epithelial cells. Once absorbed, it demonstrates potent anti-inflammatory effects in murine colitis models by downregulating inflammatory cascades without systemic toxicity.
How is KPV stored and stabilized in a laboratory setting?
Like many short linear peptides, KPV is highly susceptible to enzymatic degradation in solution. It is typically stored as a lyophilized powder at -20°C and reconstituted immediately prior to in-vitro application to prevent hydrolysis and aminopeptidase cleavage.
What antimicrobial properties have been reported for KPV?
In-vitro assays have shown that KPV possesses fungicidal and antimicrobial properties, particularly against strains like Candida albicans. Researchers hypothesize this occurs through direct interaction with the microbial membrane, independent of its anti-inflammatory pathways.